Plain-English translation of NCT07550296 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
When you have an acute ischemic stroke caused by a blood clot in a medium or large brain vessel, time is critical. This trial is testing , a medication designed to dissolve blood clots. The study will see if giving a second dose of this medication one hour after the first dose helps patients who aren't improving as quickly as hoped.
Standard clot-busting treatment works well for some stroke patients, but about half of patients with medium-sized clots and most patients with large clots don't get the relief they need. This medication may work better than current options, so researchers want to test whether a second dose in patients who aren't improving can dissolve more clots and lead to better outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive a second dose of the medication one hour after your first dose if imaging confirms your clot is still present and you haven't improved enough. Doctors will monitor you closely with imaging scans at 24 hours and again at 90 days to check if the clot dissolved and how well you're recovering. The study mainly involves standard hospital care for stroke with the addition of this second medication dose and follow-up assessments.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
China